Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
High mobility group box 1 pseudogene 22 (HMGB1P22) is a pseudogene, meaning it is a genomic locus that resembles a functional gene (in this case, the HMGB1 gene) but is typically considered nonfunctional due to accumulated mutations that prevent expression or function[1][3]. Pseudogenes like HMGB1P22 can sometimes be transcribed, and recent research shows that some pseudogene transcripts may have regulatory roles, such as acting as competitive endogenous RNAs (ceRNAs) to modulate the expression of their parent genes by sequestering microRNAs; however, there is no specific evidence that HMGB1P22 is transcribed, encodes a protein, or has a defined biological role[2][5]. Pseudogenes are increasingly recognized for their potential involvement in gene regulation, but for HMGB1P22, no detailed functional, disease, or therapeutic information is currently available in the scientific literature[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on High mobility group box 1 pseudogene 22 (HMGB1P22).